Programmed Cell Death-1/Programmed Death-Ligand 1 Blockade Improves Survival of Animals with Sepsis: A Systematic Review and Meta-Analysis

被引:5
|
作者
Zhang, Qiang [1 ]
Qi, Zhijiang [1 ]
Bo-Liu [1 ]
Li, Chun-Sheng [1 ]
机构
[1] Capital Med Univ, Beijing Chao Yang Hosp, Beijing Key Lab Cardiopulm Cerebral Resuscitat, Beijing 100020, Peoples R China
关键词
INDUCED IMMUNOSUPPRESSION; ANTI-PD-L1; ANTIBODY; ADVANCED CANCER; EXPRESSION; PD-1; MORTALITY; IMMUNOTHERAPY; INCREASES; INFECTION; DISEASES;
D O I
10.1155/2018/1969474
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Object. To investigate effects of programmed cell death-1 (PD-1) related blockade in sepsis animals. Methods. Two reviewers independently searched electronic databases including PubMed, EMBASE, and the Cochrane Library up to February 2017. Strict literature retrieval and data extraction were performed to extract relevant data. Data analysis was conducted using RevMan 5.3 software and Stata version 12.0. And relative risks (RRs) for survival rate were calculated. A fixed-effect model was selected to pool and a forest plot was used to display RRs. Results. Four studies involving 394 animals were finally included. Nine control groups are used to pool. A fixed-effect model was applied to estimate a pooled RR of 2.19 (95% CI: 1.74-2.76), indicating that PD-1 related blockade increased survival rate in sepsis animals. Conclusion. We concluded that PD-1 related blockade can improve survival of animals with sepsis. But robust standardized clinical experiments for sepsis patients are highly desirable.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis
    Liu Qiang
    Li Chun-Sheng
    [J]. 中华医学杂志(英文版), 2017, (08) : 986 - 992
  • [2] Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis
    Liu, Qiang
    Li, Chun-Sheng
    [J]. CHINESE MEDICAL JOURNAL, 2017, 130 (08) : 986 - 992
  • [3] Efficacy and Safety of Programmed Death-1/Programmed Death-Ligand 1 Inhibitor for Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis
    Liao, Pei-Fei
    Wang, Ping-Yu
    Peng, Tzu-Rong
    [J]. CURRENT ONCOLOGY, 2023, 30 (11) : 9940 - 9952
  • [4] Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis
    Zhang, Chen
    Yang, Qing
    [J]. FRONTIERS IN ONCOLOGY, 2021, 10
  • [5] Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma
    Cheah, Chan Yoon
    Fowler, Nathan H.
    Neelapu, Sattva S.
    [J]. CURRENT OPINION IN ONCOLOGY, 2015, 27 (05) : 384 - 391
  • [6] Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway
    Wang, Tianyu
    Wu, Xiaoxing
    Guo, Changying
    Zhang, Kuojun
    Xu, Jinyi
    Li, Zheng
    Jiang, Sheng
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (04) : 1715 - 1730
  • [7] Programmed death-ligand 1 expression in swine chronic infections and enhancement of interleukin-2 production via programmed death-1/programmed death-ligand 1 blockade
    Ganbaatar, Otgontuya
    Konnai, Satoru
    Okagawa, Tomohiro
    Nojima, Yutaro
    Maekawa, Naoya
    Ichikawa, Yoshiki
    Kobayashi, Atsushi
    Shibahara, Tomoyuki
    Yanagawa, Yojiro
    Higuchi, Hidetoshi
    Kato, Yukinari
    Suzuki, Yasuhiko
    Murata, Shiro
    Ohashi, Kazuhiko
    [J]. IMMUNITY INFLAMMATION AND DISEASE, 2021, 9 (04) : 1573 - 1583
  • [8] Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis
    Xu, Yimin
    Zhu, Gangcai
    Maroun, Christopher A.
    Wu, Irene X. Y.
    Huang, Donghai
    Seiwert, Tanguy Y.
    Liu, Yong
    Mandal, Rajarsi
    Zhang, Xin
    [J]. FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [9] Programmed death-ligand 1 and survival in colorectal cancers: A meta-analysis
    Cao, Huihua
    Wang, Qing
    Gao, Zhenyan
    Yu, Zhan
    Wu, Yugang
    Lu, Qicheng
    [J]. INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2019, 34 (04): : 356 - 363
  • [10] Rare Adverse Events with Programmed Death-1 and Programmed Death-Ligand 1 Inhibitors: Justification and Rationale for a Systematic Review
    Caleb J. Smith
    Yahya Almodallal
    Aminah Jatoi
    [J]. Current Oncology Reports, 2021, 23